Racecadotril

Racecadotril

SCHEMBL373243

CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MME

The experimentally established mechanism targets of Racecadotril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME known ✓ P08473 6/20 0.47
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2C9 P11712 1/20 1.00
CYP2C19 P33261 1/20 1.00
ABCC3 O15438 1/20 1.00
NR1I2 O75469 1/20 1.00
ABCB11 O95342 1/20 1.00
NR3C1 P04150 1/20 1.00
RARG P13631 1/20 1.00
CNR1 P21554 1/20 1.00
OPRK1 P41145 1/20 1.00
NR1H2 P55055 1/20 1.00
PPARA Q07869 1/20 1.00
NR1H3 Q13133 1/20 1.00
NR1I3 Q14994 1/20 1.00
HRH4 Q9H3N8 2/20 0.73
ECE1 P42892 2/20 0.47
ACE P12821 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dexecadotril SCHEMBL1649041 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Ecadotril SCHEMBL48974 1.00 CYP1A2 (1.00) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Racecadotril SCHEMBL16098141 0.99 CYP1A2 (0.98) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Dexecadotril SCHEMBL28209442 0.94 CYP1A2 (0.88) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10955802 0.94 PPARA (0.88) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
Racecadotril SCHEMBL16098344 0.91 CYP1A2 (0.82) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL8165601 0.89 CYP1A2 (0.80) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10956150 0.89 CYP1A2 (0.80) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10952774 0.87 CYP1A2 (0.78) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10956142 0.87 CYP1A2 (0.77) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2288 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680203-A1 COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS Prolevi Bio AB (SE) 2026-01-21 EP claimed
EP-4566590-A1 TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF Harbin Kanon Pharmaceutical Co., Ltd (CN) 2025-06-11 EP claimed
WO-2025075711-A1 METHODS AND MATERIALS FOR TREATING HYPEROXALEMIA AND/OR HYPEROXALURIA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2025-04-10 WO claimed
CN-119236095-A Inflammatory microenvironment responsive cross-linked polypeptide modified liposome 大理大学 2025-01-03 CN claimed
WO-2024189127-A1 COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS PROLEVI BIO AB (SE) 2024-09-19 WO claimed
CN-118557518-A Racecadotril nano suspension and preparation method thereof 天津汉瑞药业有限公司 2024-08-30 CN claimed
CN-117503707-B Taste-masking microsphere and preparation process and application thereof 哈尔滨市康隆药业有限责任公司 2024-08-23 CN claimed
US-12064443-B2 Compositions and methods for treating diseases associated with drug washout due to fluid secretion VANESSA RESEARCH HOLDINGS, INC. (US) 2024-08-20 US claimed
CN-118490667-A Orosity membrane, racecadotril orosity membrane agent, preparation method and preparation equipment thereof 上海欣峰制药有限公司 2024-08-16 CN claimed
CN-118453567-A Application of racecadotril or metabolite derivative thereof in preparing medicament for preventing and treating nervous system diseases 河北医科大学 2024-08-09 CN claimed
WO-2000061549-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
WO-2000061541-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
WO-2000061537-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
EP-0820439-B1 METHOD FOR THE ASYMMETRICAL SYNTHESIS OF S-ACYLATED DERIVATIVES OF 2-MERCAPTOMETHYL 3-PHENYL PROPANOIC ACID, AND USE THEREOF FOR SYNTHESISING N-(MERCAPTOACYL) AMINO ACID DERIVATIVES BIOPROJET SOC CIV (FR) 2000-05-03 EP claimed
US-6013829-A REDUCING A MALONIC DIESTER, HYDRIDING TO OBTAIN A DIOL, ACETYLATING TO OBTAIN A MONOESTER, OXIDATION, SAPONIFICATION AND THIOACYLATING; ENZYME INHIBITORS; PROTEASES; OPTICS; ANTISECRETORY AND HYPOTENSIVE AGENTS SOCIETE CIVILE BIOPROJET (FR) 2000-01-11 US claimed
EP-0937710-A1 Method for producing an optically active phenylpropionic acid derivative Ajinomoto Co., Inc. (JP) 1999-08-25 EP claimed
EP-0729936-B1 Process for the synthesis of alpha substituted acrylic acids and N-(mercaptoacyl)amino acids BIOPROJET SOC CIV (FR) 1999-07-07 EP claimed
US-5403824-A Administering a opioid, opioid-degrading enzyme inhibitor or enkephalin secretagogues or mixtures thereof; side effect reduction THE PROCTER & GAMBLE COMPANY (US) 1995-04-04 US claimed
US-5084007-A Method for chemical promotion of the effects of low current transcranial electrostimulation MALIN DAVID H (US) 1992-01-28 US claimed
WO-1991001756-A1 METHOD FOR CHEMICAL PROMOTION OF THE EFFECTS OF LOW CURRENT TRANSCRANIAL ELECTROSTIMULATION SKOLNICK MALCOLM H (US) 1991-02-21 WO claimed